Extracorporeal Shock Wave Therapy in Patients With Lipedema

Condition(s) studied

Investigational drug(s) / intervention(s)

Extracorporeal Shock Wave Therapy: Extracorporeal shock wave therapy (ESWT) will be applied to affected lower-extremity regions using a CE-marked shock wave device. Participants will receive six treatment sessions administered three times per week for two consecutive weeks. Clinical and ultrasonographic assessments will be performed before and after treatment.

Study summary

Lipedema is a chronic adipose tissue disorder characterized by pain, tenderness, disproportionate fat accumulation, and impaired quality of life. Extracorporeal shock wave therapy (ESWT) has been proposed as a non-invasive treatment option that may improve pain and tissue characteristics in patients with lipedema.

The aim of this prospective interventional study is to evaluate the effects of ESWT on pain intensity, quality of life, functional outcomes, and ultrasonographic findings in patients diagnosed with lipedema. Participants will receive a standardized ESWT protocol consisting of six treatment sessions over a two-week period. Clinical assessments and ultrasonographic examinations will be performed before and after treatment.

Eligibility

Primary outcome measure(s)

• Change in Pain Intensity Assessed by Visual Analog Scale (VAS) — Baseline and 2 weeks
  Change in pain intensity measured using the Visual Analog Scale (VAS) from baseline to post-treatment assessment.

Trial sites (1)

More Atlas University trials in Turkey

Other trials for the same condition